Scilipoti P, Moschini M, Li R, Lerner SP, Black PC, Necchi A et al (2024) The financial burden of localized and metastatic bladder cancer. Eur Urol S0302283824027441. https://doi.org/10.1016/j.eururo.2024.12.002

Longoni M, Scilipoti P, Soria F, Pradere B, Krajewski W, D’Andrea D et al Oncological outcomes in Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive bladder cancer patients: A systematic review on current treatment strategies and future perspectives. Eur Urol Oncol 2025:S2588-9311(25)00081 – 1. https://doi.org/10.1016/j.euo.2025.03.007

St-Laurent M-P, Bochner B, Catto J, Davies BJ, Fankhauser CD, Garg T et al Increasing life expectancy in patients with genitourinary malignancies: impact of treatment burden on disease management and quality of life. Eur Urol 2024:S0302-2838(24)02746–02745. https://doi.org/10.1016/j.eururo.2024.11.026

Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F et al (2022) Health-related quality of life with adjuvant nivolumab after radical resection for High-risk Muscle-invasive urothelial carcinoma: results from the phase 3 checkmate 274 trial. Eur Urol Oncol 5:553–563. https://doi.org/10.1016/j.euo.2022.02.003

Article  PubMed  PubMed Central  Google Scholar 

Witjes JA, Bruins HM, Carrión A, Cathomas R, Compérat EM, Efstathiou JA et al (2023) EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R et al (2023) Prostate Cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN 21:1067–1096. https://doi.org/10.6004/JNCCN.2023.0050

Article  PubMed  CAS  Google Scholar 

De Angelis M, Jannello LMI, Siech C, Baudo A, Di Bello F, Goyal JA et al (2025) Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma. Urologic Oncology: Seminars Original Investigations 43:62e1. https://doi.org/10.1016/j.urolonc.2024.09.015

Article  CAS  Google Scholar 

Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C et al (2024) Comparative effectiveness of neoadjuvant pembrolizumab versus Cisplatin-based chemotherapy or upfront radical cystectomy in patients with Muscle-invasive urothelial bladder cancer. Eur Urol Oncol 7:614–624. https://doi.org/10.1016/j.euo.2023.12.008

Article  PubMed  Google Scholar 

Gardner JW, Sanborn JS (1990) Years of potential life lost (YPLL)--what does it. measure? Epidemiol 1:322–329. https://doi.org/10.1097/00001648-199007000-00012

Article  CAS  Google Scholar 

Falkenbach F, Le QC, Longoni M, Marmiroli A, Catanzaro C, Nicolazzini M et al Years of life lost in metastatic and locally advanced prostate cancer. Eur Urol Oncol 2025:S2588-9311(25)00102-6. https://doi.org/10.1016/j.euo.2025.04.008

Social Security Administration (2024) https://www.ssa.gov/oact/STATS/table4c6.html (accessed February 1, 2025)

Definition of premature death - NCI Dictionary of Cancer Terms - NCI (2011) https://www.cancer.gov/publications/dictionaries/cancer-terms/def/premature-death (accessed January 22, 2025)

Lin W, Pan X, Zhang C, Ye B, Song J (2023) Impact of age at diagnosis of bladder cancer on survival: A Surveillance, Epidemiology, and end Results-Based study 2004–2015. Cancer Control 30:10732748231152322. https://doi.org/10.1177/10732748231152322

Article  PubMed  PubMed Central  Google Scholar 

Cano Garcia C, Piccinelli ML, Tappero S, Panunzio A, Barletta F, Incesu RB et al (2023) Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities. Int Urol Nephrol 55:1117–1123. https://doi.org/10.1007/S11255-023-03517-0

Article  PubMed  Google Scholar 

Longoni M, Rodriguez Peñaranda N, Marmiroli A, Falkenbach F, Le QC, Nicolazzini M et al Survival outcomes and Temporal trends of Non-Surgical management vs radical cystectomy in Non-Organ-Confined urothelial bladder cancer. Urology 2025:S0090-4295(25)00216-X. https://doi.org/10.1016/j.urology.2025.02.051

Longoni M, Di Bello F, Rodriguez Peñaranda N, Falkenbach F, Marmiroli A, Le QC et al (2024) Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer. BJU Int. https://doi.org/10.1111/bju.16622

Article  PubMed  PubMed Central  Google Scholar 

Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A et al (2019) Modeling 1-year Relapse-free survival after neoadjuvant chemotherapy and radical cystectomy in patients with clinical T2-4N0M0 urothelial bladder carcinoma: endpoints for phase 2 trials. Eur Urol Oncol 2:248–256. https://doi.org/10.1016/j.euo.2018.08.009

Article  PubMed  Google Scholar 

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. https://doi.org/10.1056/NEJMoa022148

Article  PubMed  CAS  Google Scholar 

International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177. https://doi.org/10.1200/JCO.2010.32.3139

Article  Google Scholar 

Withrow D, Pilleron S, Nikita N, Ferlay J, Sharma S, Nicholson B et al (2022) Current and projected number of years of life lost due to prostate cancer – A global study. Prostate 82:1088–1097. https://doi.org/10.1002/pros.24360

Article  PubMed  PubMed Central  Google Scholar 

Brustugun OT, Møller B, Helland Å (2014) Years of life lost as a measure of cancer burden on a National level. Br J Cancer 111:1014–1020. https://doi.org/10.1038/bjc.2014.364

Article  PubMed  PubMed Central  CAS  Google Scholar 

Afferi L, Jahn B, Kelkar AH, Dijk SW, Feldman ZM, Ward ZJ et al (2025) Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis. World J Urol 43:197. https://doi.org/10.1007/s00345-025-05584-7

Article  PubMed  CAS  Google Scholar 

Hemenway G, Lewis B, Ghatalia P, Anari F, Plimack ER, Kokate R et al (2023) Neoadjuvant chemotherapy with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in patients with muscle invasive bladder cancer: A retrospective age-stratified analysis on safety and efficacy. Eur Urol Oncol 6:431–436. https://doi.org/10.1016/j.euo.2022.06.005

Article  PubMed  Google Scholar 

Briganti A, Gandaglia G, Scuderi S, Gallina A, Colombo R, Fossati N et al (2020) Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: prospective assessment of perioperative outcomes from the PURE-01 trial. Eur Urol 77:576–580. https://doi.org/10.1016/j.eururo.2019.12.019

Article  PubMed  CAS  Google Scholar 

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with Muscle-Invasive urothelial bladder carcinoma (PURE-01): an Open-Label, Single-Arm, phase II study. J Clin Oncol 36:3353–3360. https://doi.org/10.1200/JCO.18.01148

Article  PubMed  CAS  Google Scholar 

Longoni M, Scilipoti P, Re C, Rosiello G, Nocera L, Pellegrino F et al (2024) Use of 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients. BJU Int 134:636–643. https://doi.org/10.1111/bju.16363

Article  PubMed  CAS  Google Scholar 

Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A et al (2023) Assessing the performance of 18F-FDG PET/CT in bladder cancer: A narrative review of current evidence. Cancers 15:2951. https://doi.org/10.3390/cancers15112951

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kimura S, Iwata T, Abufaraj M, Janisch F, D’Andrea D, Moschini M et al (2020) Impact of gender on chemotherapeutic response and oncologic outcomes in patients treated with radical cystectomy and perioperative chemotherapy for bladder cancer: A systematic review and Meta-Analysis. Clin Genitourin Cancer 18:78–87. https://doi.org/10.1016/j.clgc.2019.11.007

Article  PubMed  Google Scholar 

Meeks JJ, Black PC, Galsky M, Grivas P, Hahn NM, Hussain SA et al (2023) Checkpoint inhibitors in urothelial Carcinoma—Future directions and biomarker selection. Eur Urol 84:473–483. https://doi.org/10.1016/j.eururo.2023.05.011

Article  PubMed  CAS  Google Scholar 

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE et al (2019) A delay ≥ 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urol Oncol 37:116–122. https://doi.org/10.1016/j.urolonc.2018.11.011

Article  PubMed  Google Scholar